Cancer Advisor

Knowing your potential risk for developing cancer can help you weigh the risks against the benefits of different tests for your situation. According to the American Cancer Society, 1   more than 16.9 million people in the U.S. have a history of cancer. At least 1.9 million new cases will be diagnosed in 2022, which does not include a diagnosis of carcinoma in situ (noninvasive cancer). The society estimates 609,360 people will die from cancer in 2022, which is about 1,670 deaths per day. The four most common types include lung, breast, prostate and colorectal cancer. One of the screening tests commonly prescribed to rule out colorectal cancer is a colonoscopy. Colorectal cancer can start in the colon or in the rectum but the two types are grouped together since they have many of the same characteristics. 2  The society estimates that in 2022 there will be 106,180 new cases of colon cancer diagnosed and 44,850 new cases of rectal cancer. Although it remains the third leading cause of ca

Cancer is difficult to cure in later stages, so early detection is essential to curing the disease. New research finds an early detection method for many cancers that could significantly improve cancer survival rates. Cancer Growth May Rely On Metabolic Changes Increasing evidence has shown that cancer cells’ rapid growth relies on a shift in their metabolism.  Glycosaminoglycans (GAGs) are a type of sugar that plays an important part in metabolism. A 2016  study  by Gatto indicated that these sugars were excellent biomarkers to non-invasively detect kidney cancer. Using the GAGs test, patients with undetected cancer showed a 39 to 50 percent lower risk of death, and the test predicted cancer location with 89 percent accuracy. Francesco Gatto, Ph.D., study author from Chalmers University of Technology told The Epoch Times, GAGs feature structural changes in the blood and urine that appeared to be “a universal signature” across cancer types. This signature was detectable in very small,

A powerful case study and literature review published in the  International Journal of Clinical and Experimental Pathology  from 2014 highlights a phenomenon which is rarely if ever acknowledged by the conventional medical establishment, namely,  a case of the spontaneous regression of breast cancer with distant lymph node metastasis. A 52-year old female was diagnosed with a lump in her left breast which had spread metastically to a distant lymph node (armpit area). Before surgery she was found to have severe type 2 diabetes, and was treated with insulin until her high blood sugar normalized, a month later. She then underwent surgery on her left breast. Her post-surgery examination revealed the spontaneous regression of breast cancer both at the primary site and the metastatic lymph node in her armpit. Furthermore, immunohistochemical studies found that the woman’s estrogen receptor positive, AE1/AE3-positive ductal carcinoma, “…completely underwent necrosis associated with extensive

Thomas Seyfried, Ph.D., professor in the biology department at Boston College, is a leading expert and researcher in the field of cancer metabolism and nutritional ketosis. His book, "Cancer as a Metabolic Disease: On the Origin, Management and Prevention of Cancer" is a foundational textbook on this topic, and in August 2016, he received the Mercola.com Game Changer Award for his work. Here, we discuss the mechanisms of cancer and the influence of mitochondrial function, which plays a crucial role in the development and treatment of this disease. His  landmark cancer theory is available as a free PDF . Many of his views are now encapsulated in his most paper, 1  "Mitochondrial Substrate-Level Phosphorylation as Energy Source for Glioblastoma: Review and Hypothesis," published online December 27, 2018. He's also published a number of other papers 2 , 3 , 4  on the metabolic underpinnings of cancer. "The paper … is a review